### ðŸ«  Coronary Artery Disease: Diabetes Treatment with Cardioprotective Agents

#### âœ… True Statements
1. **Sodium-glucose cotransporter 2 (SGLT2) inhibitors**, such as **empagliflozin**, and **glucagon-like peptide 1 (GLP-1) receptor agonists**, such as **dulaglutide**, reduce **cardiovascular events** in patients with **type 2 diabetes mellitus (T2DM)** and **atherosclerotic cardiovascular disease (ASCVD)** or those at high risk.
2. **SGLT2 inhibitors** and/or **GLP-1 receptor agonists** are recommended for patients with **type 2 diabetes mellitus** and **established coronary artery disease (CAD)** to reduce the risk of **cardiovascular and renal events**.
3. Adding an **SGLT2 inhibitor** such as **empagliflozin** is an appropriate next step in a patient with **type 2 diabetes mellitus**, **established CAD**, and **inadequate glycemic control** (e.g., **hemoglobin A1c >8%**).
4. **Amlodipine** is an appropriate **antihypertensive and antianginal agent**, but is not indicated if **blood pressure** is well controlled and **angina symptoms** are absent.
5. **P2Y12 inhibitors** such as **clopidogrel** are not routinely used for **stable angina** and should be reserved for **acute coronary syndrome (ACS)** or **postâ€“percutaneous coronary intervention (PCI)**.
6. **Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors**, such as **evolocumab**, are indicated in patients with **ASCVD** to achieve an **LDL cholesterol** target of **<55 mg/dL (1.42 mmol/L)**.
7. Additional **lipid-lowering therapy** is not indicated when **LDL cholesterol** is already below **55 mg/dL (1.42 mmol/L)** in patients with **ASCVD**.

#### ðŸ’¬ Extra
1. Multiple randomized trials have demonstrated the cardioprotective effects of SGLT2 inhibitors and GLP-1 receptor agonists in high-risk diabetic populations.
2. These agents are used in conjunction with lifestyle modification and metformin to reduce macrovascular and microvascular complications.
3. This patient had **hemoglobin A1c of 8.4%**, suggesting suboptimal glucose control despite current therapy.
4. Amlodipine would be used if systolic blood pressure exceeded **130 mm Hg** or if **symptomatic angina** were present.
5. The use of clopidogrel in stable CAD increases bleeding risk without proven outcome benefit unless there is a **recent ACS or PCI**.
6. PCSK9 inhibitors are typically added when **statin plus ezetimibe** therapy fails to achieve LDL cholesterol goals.
7. This patientâ€™s **LDL cholesterol level is 52 mg/dL (1.35 mmol/L)**, already below the recommended target for patients with **established ASCVD**.

#### ðŸ”· Tags
#Cardiology #AmbulatoryCare #Type2Diabetes #SGLT2Inhibitor #GLP1Agonist #CoronaryArteryDisease #CardiovascularRiskReduction #GlycemicControl

#### ðŸ“™ Reference
ElSayed NA, Aleppo G, Aroda VR, et al. 10. Cardiovascular disease and risk management: standards of care in diabetes-2023. *Diabetes Care*. 2023;46:S158-S190. PMID: [36507632](https://pubmed.ncbi.nlm.nih.gov/36507632) doi:10.2337/dc23-S010

#### ðŸ†” Question ID
CVMCQ24065

#### ðŸ•’ Last Updated
February 2025

---

#### ðŸ“– Related Text
MKSAP 19: Cardiovascular Medicine â€” Coronary Artery Disease, Management of Coronary Artery Disease in Specific Populations â€” Patients With Diabetes

---

### ðŸ“˜ Related Text Derivations

#### âœ… True Statements
1. **Optimal medical therapy** for patients with **diabetes and coronary artery disease (CAD)** includes **risk factor reduction**, **glycemic control**, and **antianginal therapy**.
2. In patients with **diabetes and ASCVD**, the **target blood pressure** is **<130/80 mm Hg** if achievable without excessive treatment burden.
3. **Angiotensin-converting enzyme (ACE) inhibitors** or **angiotensin receptor blockers (ARBs)** at **maximally tolerated dosages** are preferred for **blood pressure control** due to **renal and cardiovascular protective effects**.
4. **Î²-Blockers** are indicated for patients with **established CAD**, with additional agents added if **blood pressure goals** are unmet or **symptoms persist**.
5. **High-intensity statin therapy** is recommended in patients with **diabetes and CAD**, regardless of baseline **LDL cholesterol** level.
6. **Ezetimibe** or **PCSK9 inhibitors** may be added to **statin therapy** to reduce **LDL cholesterol** by **â‰¥50% from baseline** and achieve a target of **<70 mg/dL (1.8 mmol/L)** or **<55 mg/dL (1.4 mmol/L)** in patients with prior **acute coronary syndrome (ACS)**.
7. **Icosapent ethyl** may reduce cardiovascular risk in patients with **controlled LDL cholesterol** and **elevated triglyceride levels (135â€“499 mg/dL)** while on statins.
8. **Combination therapy** of **statin plus fibrate or niacin** is **not recommended** for patients with **diabetes and CAD**.
9. **Daily aspirin (75â€“162 mg)** is recommended for **secondary prevention** in all patients with **diabetes and CAD**.
10. **P2Y12 inhibitors** (e.g., **clopidogrel**, **ticagrelor**) may be used for **secondary prevention**, but increase **bleeding risk**.
11. **Rivaroxaban 2.5 mg twice daily**, combined with **aspirin**, may be considered in patients with **CAD or peripheral artery disease (PAD)** and **low bleeding risk** to reduce **major adverse limb and cardiovascular events**.
12. **SGLT2 inhibitors** and/or **GLP-1 receptor agonists** are recommended for patients with **type 2 diabetes mellitus and CAD** to reduce **cardiovascular and renal events**.

#### ðŸ’¬ Extra
1. Components of optimal medical therapy include exercise, weight loss, and smoking cessation in addition to pharmacotherapy.
2. Guideline-directed blood pressure targets aim to reduce stroke and cardiovascular risk in high-risk diabetic populations.
3. These agents also delay progression of diabetic nephropathy and reduce heart failure risk.
4. Î²-Blockers reduce myocardial oxygen demand and are used for symptom control and secondary prevention.
5. Even with normal baseline LDL, high-intensity statins reduce events in secondary prevention.
6. More aggressive LDL targets are used post-ACS due to higher residual risk.
7. Icosapent ethyl benefits patients with **high triglycerides** despite statin use, per REDUCE-IT trial.
8. Fibrate and niacin combinations have not improved outcomes and may increase adverse effects.
9. Aspirin use in this setting is well established for secondary prevention of cardiovascular events.
10. The bleeding risk must be carefully balanced against potential ischemic benefits.
11. This approach follows the COMPASS trial strategy for dual pathway inhibition.
12. These therapies are now core components of guideline-directed diabetes care with CAD.

#### ðŸ”· Tags
#Diabetes #Cardiology #SGLT2Inhibitor #GLP1Agonist #Atherosclerosis #RiskFactorModification #Statins #PCSK9Inhibitor #AntiplateletTherapy #BloodPressureControl #SecondaryPrevention

---

#### ðŸ§¾ Supplemental Table

<!-- Medical Therapy for Acute Coronary Syndromes and Angina -->
<table>
  <caption><strong>Medical Therapy for Acute Coronary Syndromes and Angina</strong></caption>
  <thead>
    <tr>
      <th>Medication</th>
      <th>Drugs in Class</th>
      <th>Dosage</th>
      <th>Indications</th>
      <th>Comments</th>
    </tr>
  </thead>
  <tbody>
    <!-- Antiplatelet Medications -->
    <tr><td colspan="5"><strong>Antiplatelet Medications</strong></td></tr>
    <tr>
      <td><strong>Aspirin</strong></td>
      <td>N/A</td>
      <td>81â€“162 mg/d</td>
      <td>All patients with acute coronary syndrome (ACS), unless intolerant or allergic.<br>All patients with angina.<br>Aspirin desensitization may be considered for patients with allergy.</td>
      <td>Nonenteric formulation recommended for aspirin-naive patients with ACS.</td>
    </tr>
    <tr>
      <td><strong>Clopidogrel</strong></td>
      <td>N/A</td>
      <td>75 mg/d</td>
      <td>P2Y<sub>12</sub> inhibitor in combination with aspirin is indicated in all patients after ACS for at least 1 year.</td>
      <td>Alternative to aspirin for patients with stable coronary artery disease (CAD) and aspirin intolerance or allergy.</td>
    </tr>
    <tr>
      <td><strong>Prasugrel</strong></td>
      <td>N/A</td>
      <td>10 mg/d</td>
      <td>P2Y<sub>12</sub> inhibitor with aspirin indicated after ACS if PCI is performed. Not used before coronary angiography.</td>
      <td>Contraindicated if age >75 or history of stroke/TIA. Adjust to 5 mg/d if weight &lt;60 kg (132 lb).</td>
    </tr>
    <tr>
      <td><strong>Ticagrelor</strong></td>
      <td>N/A</td>
      <td>90 mg twice daily</td>
      <td>P2Y<sub>12</sub> inhibitor in combination with aspirin is indicated in all patients after ACS for at least 1 year.</td>
      <td>Faster onset; no first-pass hepatic metabolism; no known genetic polymorphisms. Higher bleeding risk with aspirin &gt;100 mg.</td>
    </tr>
    <!-- Cardioprotective Medications -->
    <tr><td colspan="5"><strong>Cardioprotective Medications</strong></td></tr>
    <tr>
      <td><strong>Î²-Blockers</strong></td>
      <td>Atenolol, metoprolol, carvedilol, nebivolol, bisoprolol</td>
      <td>Variable</td>
      <td>All patients with prior myocardial infarction (MI) or LV systolic dysfunction (only metoprolol succinate, carvedilol, or bisoprolol).<br>Angina.</td>
      <td>Avoid in cardiogenic shock, hypotension, or conduction disturbances.</td>
    </tr>
    <tr>
      <td><strong>ACE Inhibitors</strong></td>
      <td>Benazepril, captopril, enalapril, fosinopril, perindopril, trandolapril, lisinopril, ramipril, quinapril</td>
      <td>Variable</td>
      <td>All patients with LV systolic dysfunction, hypertension, diabetes mellitus, or kidney disease.</td>
      <td>Especially beneficial in anterior MI.</td>
    </tr>
    <tr>
      <td><strong>Angiotensin Receptor Blockers</strong></td>
      <td>Losartan, valsartan, olmesartan, candesartan, irbesartan, telmisartan</td>
      <td>Variable</td>
      <td>All patients with LV systolic dysfunction, hypertension, diabetes, or kidney disease who are intolerant of ACE inhibitors.</td>
      <td>Should not be combined with ACE inhibitors.</td>
    </tr>
    <tr>
      <td><strong>Aldosterone Inhibitor</strong></td>
      <td>Eplerenone</td>
      <td>25â€“50 mg/d</td>
      <td>Patients with STEMI with LVEF â‰¤40% and either clinical heart failure or diabetes.</td>
      <td>Use caution in chronic kidney disease or hyperkalemia.</td>
    </tr>
    <tr>
      <td><strong>High-Intensity Statins</strong></td>
      <td>Atorvastatin, Rosuvastatin</td>
      <td>Atorvastatin 40â€“80 mg/d<br>Rosuvastatin 20â€“40 mg/d</td>
      <td>All patients with CAD and age â‰¤75 years.</td>
      <td>â€”</td>
    </tr>
    <tr>
      <td><strong>Moderate-Intensity Statins</strong></td>
      <td>Atorvastatin, Rosuvastatin, Simvastatin, Pravastatin, Lovastatin, Fluvastatin</td>
      <td>10â€“40 mg/d depending on agent</td>
      <td>All patients with CAD and age &gt;75 years or who are statin intolerant.</td>
      <td>Simvastatin limited to 20 mg/d if using amlodipine.</td>
    </tr>
    <!-- Antianginal Medications -->
    <tr><td colspan="5"><strong>Antianginal Medications</strong></td></tr>
    <tr>
      <td><strong>Nitroglycerin</strong></td>
      <td>Sublingual, Oral, IV</td>
      <td>Sublingual: 0.4 mg q5min Ã—3<br>IV: 5â€“10 Î¼g/min initial infusion</td>
      <td>Chest pain relief; IV for persistent pain, heart failure, or hypertension.</td>
      <td>Avoid with SBP &lt;90 or â‰¥30 mmHg drop, RV infarction, PDE-5 inhibitors, HCM, or AS.</td>
    </tr>
    <tr>
      <td><strong>Dihydropyridine Calcium Channel Blockers</strong></td>
      <td>Amlodipine</td>
      <td>5â€“10 mg/d</td>
      <td>BP control and angina in hypertensive patients.</td>
      <td>Careful dose titration due to delayed onset.</td>
    </tr>
    <tr>
      <td><strong>Nondihydropyridine Calcium Channel Blockers</strong></td>
      <td>Diltiazem, Verapamil</td>
      <td>Variable</td>
      <td>For patients with NSTE-ACS and angina intolerant to or refractory to Î²-blockers and nitrates.</td>
      <td>Contraindicated in STEMI, heart failure, or AV block.</td>
    </tr>
    <tr>
      <td><strong>Ranolazine</strong></td>
      <td>â€”</td>
      <td>500â€“1000 mg twice daily</td>
      <td>For angina refractory to other therapies. No meaningful HR or BP effect.</td>
      <td>QT-prolonging; reduce dose with CYP3A4 inhibitors. Avoid in cirrhosis.</td>
    </tr>
  </tbody>
  <tfoot>
    <tr>
      <td colspan="5">
        <em>
          ACS = acute coronary syndrome; AS = aortic stenosis; BP = blood pressure; CAD = coronary artery disease;
          CYP450 3A4 = cytochrome P-450 3A4; HCM = hypertrophic cardiomyopathy; IV = intravenous;
          LV = left ventricular; LVEF = left ventricular ejection fraction; MI = myocardial infarction;
          N/A = not applicable; NSTE-ACS = nonâ€“ST-elevation acute coronary syndrome; PCI = percutaneous coronary intervention;
          PDE-5 = phosphodiesterase 5; RV = right ventricular; SBP = systolic blood pressure;
          SL = sublingual; STEMI = ST-elevation myocardial infarction; TIA = transient ischemic attack.
        </em>
      </td>
    </tr>
  </tfoot>
</table>